Paper41598623
Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone.
Kawczak P and 1 other. J Clin Med, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone. Papers, record 41598623. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41598623
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References225
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41217772 | Lutetium Lu 177 vipivotide tetraxetan: A literature review. | J Oncol Pharm Pract | 2026 | https://conductscience.org/library/papers/41217772 | PubMed |
| 2 | 38614820 | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. | Eur Urol | 2024 | https://conductscience.org/library/papers/38614820 | PubMed |
| 3 | 21807635 | Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21807635 | PubMed |
| 4 | 23228172 | Abiraterone in metastatic prostate cancer without previous chemotherapy. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23228172 | PubMed |
| 5 | 39577422 | Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. | Cancer Cell | 2024 | https://conductscience.org/library/papers/39577422 | PubMed |
| 6 | 35599144 | Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. | Eur Urol Oncol | 2022 | https://conductscience.org/library/papers/35599144 | PubMed |
| 7 | 39060912 | Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. | Drugs | 2024 | https://conductscience.org/library/papers/39060912 | PubMed |
| 8 | 30310278 | Targeted nonviral gene therapy in prostate cancer. | Int J Nanomedicine | 2018 | https://conductscience.org/library/papers/30310278 | PubMed |
| 9 | 39123395 | Development of a Multidisciplinary Care Pathway for Fracture Prevention in Men with Prostate Cancer at Initiation of Androgen Deprivation Therapy. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39123395 | PubMed |
| 10 | 31482746 | The current status of the clinical utility of liquid biopsies in cancer. | Expert Rev Mol Diagn | 2019 | https://conductscience.org/library/papers/31482746 | PubMed |
| 11 | 40299225 | Advances in Targeted Therapy for Metastatic Prostate Cancer. | Curr Treat Options Oncol | 2025 | https://conductscience.org/library/papers/40299225 | PubMed |
| 12 | 35273651 | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. | Ther Adv Med Oncol | 2022 | https://conductscience.org/library/papers/35273651 | PubMed |
| 13 | 23863050 | Alpha emitter radium-223 and survival in metastatic prostate cancer. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23863050 | PubMed |
| 14 | 31732676 | Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. | J Nucl Med | 2020 | https://conductscience.org/library/papers/31732676 | PubMed |
| 15 | 32820953 | The potential of PSMA-targeted alpha therapy in the management of prostate cancer. | Expert Rev Anticancer Ther | 2020 | https://conductscience.org/library/papers/32820953 | PubMed |
| 16 | 19487300 | Adaptive therapy. | Cancer Res | 2009 | https://conductscience.org/library/papers/19487300 | PubMed |
| 17 | 29635390 | RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29635390 | PubMed |
| 18 | 40864353 | Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions. | Curr Oncol Rep | 2025 | https://conductscience.org/library/papers/40864353 | PubMed |
| 19 | 40940844 | The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940844 | PubMed |
| 20 | 41038711 | Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/41038711 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42745883 | PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42745883 | PubMed |
| 42729212 | Association of selected ELAC2, MSR1, RNASEL and KLK3 polymorphisms with prostate cancer susceptibility in a Hungarian cohort. | Pathol Oncol Res | 2026 | https://conductscience.org/library/papers/42729212 | PubMed |
| 41827159 | Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine. | J Clin Med | 2026 | https://conductscience.org/library/papers/41827159 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
| FOLH1 | 2346 | PubTator's text mining | https://conductscience.org/library/genes/2346 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41598623
GET https://conductscience.org/api/papers/v1/41598623/references?page=2